Presentation is loading. Please wait.

Presentation is loading. Please wait.

The Transition to Industry Biology in the Private Sector.

Similar presentations


Presentation on theme: "The Transition to Industry Biology in the Private Sector."— Presentation transcript:

1 The Transition to Industry Biology in the Private Sector

2 Topics: Types of Private-sector Positions for Biologists Key Differences Between Academia/Private Sector Different workplaces and job types in Pharmaceutical/Biotechnology Companies Research Areas Important Website But, can you go home again?

3 Jobs in the Private Sector 1.The Pharmaceutical and Biotech Industries. The Quest for Therapeutics. Many Companies Have Research Programs as Rigorous as Found in Academia. 2.Contract Research Laboratories (For-profit and Non-profit). “Science for Hire.” Work is Very Specific, Task-oriented.

4 Key Differences from Academia Tenure You Work as Part of a Team “Freedom” of Research Pursuits Hiring: Academia- Research Program Private Sector – Meet Immediate Need

5 Pharmaceutical/Biotech Industries (What’s Your Adrenaline Level?) Small StartupCompaniesLarger Established Companies Fewer People – Wear Many Hats Excitement for Company’s Mission Risky – Can be Lucrative or “Live Fast, Die Young Leave a Beautiful Corpse.” More Stable. Infrastructure in Place. Not as Diverse People Interactions as Startups Capital for Equipment More Available.

6 Some Key Therapeutic Targets Cancer – So much more is known now than 1972. >500 potential therapeutics in clinical trials. Mortality rates overall not greatly changed. Infectious Diseases – Microbial Mutation = Never- ending Battle. Clues from sequencing studies for new targets. Neurodegenerative Diseases – Alzheimer's (5 million in US currently), ALS, Parkinson's, etc. Immune Disorders/Inflammatory Diseases – Autoimmune diseases, Asthma. No new Lupus therapeutic in 30 years.

7 Two Major “Camps” in Pharma/Biotech DRUG DISCOVERY Basic Research for Efficacy Mechanism of Action Studies Technological Advances (Mouse Models, Sequencing, Mass Spec) Make It a Very Exciting Time in Discovery DRUG DEVELOPMENT Later Stage, When Therapeutic Looks Promising Safety Testing (Toxicology) Highly Regulated Science (GLPs - Must have SOPs, Validated Methods, Evidence of Equipment Calibration and Personnel Training.)

8 Get Familiar with Biospace.com:

9 Can You Return to Academia? Yes…But You Must Be Able to Publish!

10 Summary Exciting Time for Biotechnology Fulfillment of Bringing Therapeutics to Patients Roller Coaster or Merry-go-round? Ready to Put the Team First? Consider a Postdoc Position in Industry. Biospace.com Return to Academia? Make Sure You Can Publish.


Download ppt "The Transition to Industry Biology in the Private Sector."

Similar presentations


Ads by Google